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Lafora disease (LD, OMIM 254780) is a rare fatal neurodegenerative disorder that usually 
occurs during childhood with generalized tonic-clonic seizures, myoclonus, absences, drop 
attacks or visual seizures. Unfortunately, at present, available treatments are only palliatives 
and no curative drugs are available yet. The hallmark of the disease is the accumulation of 
insoluble polyglucosan inclusions, called Lafora bodies (LBs), within the neurons but also in 
heart, muscle and liver cells. Mouse models lacking functional EPM2A or EPM2B genes (the 
two major loci related to the disease) recapitulate the Lafora disease phenotype: they 
accumulate polyglucosan inclusions, show signs of neurodegeneration and have a 
dysregulation of protein clearance and endoplasmic reticulum stress response. In this study, 
we have subjected a mouse model of LD (Epm2b-/-) to different pharmacological 
interventions aimed to alleviate protein clearance and endoplasmic reticulum stress. We have 
used two chemical chaperones, trehalose and 4-phenylbutyric acid. In addition, we have used 
metformin, an activator of AMP-activated protein kinase (AMPK), as it has a recognized 
neuroprotective role in other neurodegenerative diseases. Here, we show that treatment with 
4-phenylbutyric acid or metformin decreases the accumulation of Lafora bodies and 
polyubiquitin protein aggregates in the brain of treated animals. 4-Phenylbutyric acid and 
metformin also diminish neurodegeneration (measured in terms of neuronal loss and reactive 
gliosis) and ameliorate neuropsychological tests of Epm2b-/- mice. As these compounds have 
good safety records and are already approved for clinical uses on different neurological 
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Lafora disease (LD, OMIM 254780) is a rare fatal neurodegenerative disorder that usually 
occurs during childhood with generalized tonic-clonic seizures, myoclonus, absences, drop 
attacks or visual seizures ([1], [2]). Unfortunately, at present, available treatments are only 
palliatives and no curative drugs are available yet. The hallmark of the disease is the 
accumulation of insoluble polyglucosan inclusions, called Lafora bodies (LBs), within the 
neurons but also in heart, muscle and liver cells. Recessive mutations in two main loci, 
EPM2A and EPM2B, are known to produce LD ([3], [4], [5]). EPM2A gene encodes the 
glucan phosphatase laforin and EPM2B gene encodes the E3-ubiquitin ligase malin. Although 
it is known that both proteins form a functional complex ([6], [7], [8]), the underlying 
molecular mechanisms of this pathology are not fully understood. In this sense, although 
laforin and malin have been involved in the regulation of glycogen metabolism, recent reports 
indicate that they also play a role in alternative physiological pathways such as endoplasmic 
reticulum stress response ([9], [10], [11]) and protein clearance ([10], [12], [13], [14]). 
Protein homeostasis (proteostasis) is achieved by the coordinated action of an efficient 
folding and transport of newly synthesized proteins and an active quality control with 
degradative mechanisms to reduce the load of unfolded/misfolded proteins thereby to prevent 
abnormal protein aggregation [15]. When the folding capacity is saturated, 
unfolded/misfolded proteins are usually tagged with ubiquitin moieties to target them for 
proteasome and/or lysosomal degradation. If these protein clearance mechanisms are not 
efficient then unfolded/misfolded proteins accumulate and tend to form oligomeric structures. 
Thus, the presence of protein aggregates is an indication of an altered proteostasis [15]. LBs 
contain, in addition to insoluble glycogen-like polysaccharides (polyglucosans), ubiquitinated 
proteins, advanced glycation-end products, chaperones, autophagy components and 
proteasome subunits ([12], [16]). Therefore LD can be considered as another example of 
proteostasis dysfunction in which as indicated above, protein clearance and endoplasmic 
reticulum stress are defective. So, we reasoned that the use of compounds that could alleviate 
proteostasis dysfuction could be beneficial in the treatment of LD. In this sense, in this work 
we have used 4-phenylbutyric acid (4-PBA), a chemical chaperone that reverses misfolding 
and aggregation of proteins associated with several human neurodegenerative diseases ([17], 
[18], [19]) and trehalose, a non-reducing disaccharide that also acts as a chemical chaperone 
preventing protein denaturation and protecting cell integrity against several stresses ([20], 
[21]). 
AMP-activated protein kinase (AMPK) is a heterotrimeric enzyme consisting in one 
catalytic AMPKone scaffold AMPK and one regulatory AMPK subunit, that senses 
energy status in cells and responds to drops in ATP by inhibiting catabolic and activating 
anabolic pathways, to restore ATP homeostasis ([22] [23]). AMPK also plays a role in 
promoting autophagy by inhibiting mTOR kinase or by phosphorylating ULK1 [23]. As it has 
been reported that AMPK activation plays a neuroprotective role in different 
neurodegenerative diseases ([24], [25], [26], [27]), we checked whether metformin, an 
activator of AMPK widely used in the treatment of type2 diabetes, could have a beneficial 
effect on LD. 
Our results indicate that among the drugs mentioned above, 4-PBA and metformin 
have a clear beneficial effect on all the assayed neurophatological symptoms of Epm2b-/- 
mice. 
 
MATERIAL AND METHODS 
Ethic statement, animal care, mice and husbandry 
This study was carried out in strict accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the Consejo Superior de Investigaciones Cientificas 
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(CSIC, Spain). All mouse procedures were approved by the animal committee of the Instituto 
de Biomedicina de Valencia-CSIC [Permit Number: INTRA12 (IBV-4)]. All efforts were 
made to minimize animal suffering. To minimize the effect of differences in the genetic 
background of the animals, and since LD is a recessive autosomal disorder, we crossed 
Epm2b-/- mice (with a mixed background 129sv:C57BL/6) previously described [14] with 
control C57BL/6JRccHsd mice obtained from Harlan laboratories (Barcelona, Spain) to 
obtain heterozygous Epm2b+/- mice. These were crossed among them to obtain heterozygous 
Epm2b+/- (used as control) and homozygous Epm2b-/- littermates, that were used in this 
study. Mice were maintained in the IBV-CSIC facility on a 12/12 light/dark cycle under 
constant temperature (23°C) with food and water provided ad libitum. 
 
Pharmacological interventions 
Trehalose, metformin and 4-phenylbutyric acid (4-PBA), all these compounds having good 
safety records and already approved for clinical uses on different neurological pathologies, 
were purchased from Sigma (Madrid, Spain). Trehalose (2%), metformin (12 mM) and 4-PBA 
(20 mM) were administered dissolved in the drinking water. Epm2b+/- (control) and Epm2b-
/- (KO) male mice (groups of 8-12 animals) at three months of age (we chose this age because 
at this time the Emp2b-/- mice clearly show the presence of Lafora bodies in the brain and 
they are at the beginning of their neurological impairment) were treated or not with trehalose, 
4-PBA or metformin. Treatments were applied for one month, and mice were subjected to the 
behavioral tests described below. Then, treatment was continued for an extra month. After this 
period, mice were subjected again to the same behavioral tests and sacrificed by cervical 
dislocation. Brain was recovered, cut in two equal pieces, one part conserved at -80ºC for 
processing for western blot analyses, and the other part fixed in 4% paraformaldehyde in 
phosphate buffer saline (PBS) and dehydrated for posterior histological analyses. 
 
Histological and immunohistofluorescence analyses. 
Dehydrated tissues were embedded in paraffin and sectioned at 4 µm. For periodic acid-Schiff 
(PAS) staining, sections were deparaffined, rehydrated and incubated with 1% periodic acid 
for 7 min, followed by additional 21 min incubation with Schiff reagent (Sigma, Madrid, 
Spain). Alternatively, for immunohistochemistry analyses (IHC), sections were deparaffined, 
rehydrated, and warmed at 95°C for 30 min in 10 mM citrate buffer for antigen retrieval. 
Sections were blocked in blocking buffer (3% BSA - 3% fat-free milk proteins, in PBS) and 
incubated overnight at 4°C with primary antibody diluted at 1/200 in blocking buffer [anti-
NeuN, (Millipore, Madrid, Spain)]. After three washes of 10 min in PBS, sections were 
incubated for one hour at room temperature with the biotin-conjugated rabbit secondary 
antibody diluted at 1/250 in blocking buffer, washed three times with PBS for 5 min, 
incubated with the immunopure ABC kit (Fisher scientific, Madrid, Spain) for 30 min in 
darkness, washed three times in PBS for 5 min and developed with using metal enhanced dab 
method (Fisher scientific). Both PAS staining than IHC sections were finally counterstained 
with haematoxylin (Sigma, Madrid, Spain), dehydrated and mounted in DPX (Merck, 
Germany). For immunohistofluoresence analyses (IHF), sections were deparaffined, 
rehydrated, incubated for 20 min in sodium borohydrate (1 mg/ml) to lower background and 
warmed at 95°C for 30 min in 10 mM citrate buffer for antigen retrieval. Sections were 
blocked in blocking buffer (3% BSA - 3% fat-free milk proteins, in PBS) and incubated 
overnight at 4°C with primary antibody diluted at 1/250 in blocking buffer [anti-
polyubiquitin, (Enzo Life Sciences, Madrid, Spain) or anti-GFAP (Sigma, Madrid, Spain)]. 
After three washes of 10 min in PBS, sections were incubated for one hour at room 
temperature with the appropriate secondary antibody diluted at 1/200 in blocking buffer, 
washed once with PBS, incubated with DAPI (Sigma, Madrid, Spain), washed twice with 
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PBS and mounted in FluoMount (Polysciences Inc., USA). Images were acquired with a 
DM6000 Leica Microscope and fluorescence was quantified using Image J software (NIH, 
USA). 
 
Western blot analyses 
Mouse brain homogenates were lysed in RIPA buffer [20 mM Tris-HCl, pH 7.5; 150 mM 
NaCl; 1 mM EDTA; 1 mM EGTA; 1% NP-40; 1% sodium deoxycholate; 1 mM Na3VO4 and 
complete protease inhibitor cocktail (Roche, Spain)] for 20 min at 4°C and centrifuged at 
10,000 g for 15 min. The supernatants were collected and 25 µg of total protein subjected to 
SDS-PAGE, transferred into PVDF membrane and revealed with the appropriated antibodies, 
using Li-Cor protocol and the Odissey software (LI-COR Corporate, USA). The antibodies 
used in this study were anti-BiP/GRP78, anti-pThr172-AMPKalpha anti-AMPKbeta1/2, anti-
pS641-glycogen synthase, anti-glycogen synthase kinase 3b, anti-pSer9-glycogen synthase 
kinase 3b, from Cell Signaling Technology Inc. (Barcelona, Spain); anti-LC3B and anti-actin 
from Sigma (Madrid, Spain); anti-p62 from Abcam (Cambridge, UK); anti-glycogen synthase 
(Epitomics, Burlingame, USA). 
 
Behavioral tests 
Mouse neuropsychological behavior was examined using a selection of standard tests. Briefly, 
the tests were conducted as follow: 
Tail Suspension Test (TST): It was performed as indicated in [28]. Mice were 
suspended at 15 cm height by the tail for 30s and the foot-clasping posture was scored as 
follows: 0, with both extended feet and 1, with one clasped foot, alternative foot-clasping or 
with both clasped feet. 
Vertical Pole Test: It was performed as indicated in [29]. Mice were placed head 
upward near the top of a vertical rough-surfaced pole (diameter 10 mm, height 51 cm). The 
time taken for the mice to turn completely downward (time to turn) and the total time taken to 
reach the floor (locomotion activity time) were recorded, with a cut-off limit of 120s for the 
combined movements.  
Open Field Test: It was performed as indicated in [30]. Mice were placed in the left-
bottom corner of a dark square open field (40cm x 40cm x 40cm) and exploration was tracked 
for 20 min. Distance, immobility, spent time and number of entries into 3 concentric zones 
were measured with the Smart software (PanLab, Barcelona, Spain). 
Beam-balance Test: It was performed as indicated in [31]. The mouse’s home-cage 
was placed at one end of an 80 cm long beam of 26, 12 or 5 mm width and the start point was 
the other wider end of the beam. The tapered beam had ledges (2 cm wide) that provide 
“safety” when the mouse’s foot slipped off of the beam. The mouse was given a single trial to 
learn to walk from the start of the beam to its home-cage. Once the mouse reached its home-
cage, it was permitted to remain in the cage to reinforce the target location. The mouse was 
given three additional trials, each separated by the 60s reinforcement. Time to cross the beam 
was recorded with a cut-off limit of 120s. 
 
Statistical analysis 
The data were expressed as mean ± standard error of the mean (SEM). Statistical significance 
was determined as indicated in each case by Kruskall-Wallis test, followed by Conover-
Inman’s multiple comparison test, by Fisher exact test or by Wilcoxon-Mann-Whitney test 







The different treatments affect their corresponding molecular targets. 
In order to find a beneficial treatment for LD, we used different strategies aimed either to 
alleviate proteostasis, which is impaired in the disease, or to activate AMPK, since as 
indicated above, activation of this kinase plays a neuroprotective role in different 
neurodegenerative diseases. Three-month old male heterozygous Epm2b+/- (control) and 
homozygous Epm2b-/- (KO) mice were subjected to different pharmacological interventions 
[trehalose and 4-phenylbutiric acid (4-PBA) to alleviate proteostasis dysfunction, and 
metformin, to activate AMPK], and after the treatment period, mice were subjected to 
different behavioral tests, sacrificed by cervical dislocation and brain was recovered for 
biochemical and histological analyses. 
 We first checked by western blot analyses of total brain extracts the efficiency of the 
different drugs in affecting their corresponding anticipated molecular targets. Trehalose and 4-
PBA may both act as chemical chaperones to relieve proteostasis dysfucntion. In agreement 
with this assumption, we found that after two months of treatment with any of these 
compounds, there was an increase in the levels of the chaperone BiP/GRP78, in both control 
(Epm2b+/-, p=0.006 w/o TTT vs trehalose and p=0.03 w/o TTT vs 4-PBA) and KO malin 
(Epm2b-/-, p=0.002 w/o TTT vs trehalose and p=0.007 w/o TTT vs 4-PBA) mice (Fig. 1A). 
No significant differences were observed between the untreated samples of control (Epm2b+/-
) and KO (Epm2b-/-) mice at this age, in agreement with previous results [10]. On the other 
hand, treatment with metformin for two months induced the activation of AMPK in both 
control (p=0.03) and KO malin mice (p=0.03), as indicated by higher levels of the 
phosphorylated form of the catalytic subunit of the AMPK complex (pThr172-AMPKalpha) 
(Fig. 1B). In this case we use the levels of AMPK subunits as loading control, since this 
antibody gives better results than the anti-AMPK antibody when analyzing endogenous 
levels of the trimeric AMPK complex. 
 
4-PBA or metformin treatments decrease the accumulation of polyglucosan inclusions 
and polyubiquitinated protein aggregates. 
Next, we investigated the effects of all drugs on the formation of polyglucosan inclusions 
(that stained positive with the periodic acid-Schiff protocol; PAS+), the hallmark of LD, in 
different brain areas: cerebellum, pontine, hippocampus, olfactory bulb, cortex and midbrain. 
As observed in Fig. 2, no PAS+ inclusions were detected in the brain areas of control 
(Epm2b+/-) mice. However, untreated Epm2b-/- mice accumulated polyglucosan inclusions in 
different areas with different extent, with higher levels in cerebellum, pontine and 
hippocampus and lower levels in olfactory bulb, cortex and midbrain (Fig. 2B, white bars). 
The treatment with trehalose did not modify the accumulation of PAS+ granules (Fig. 2A and 
2B). However, treatment with 4-PBA or metformin clearly reduced the number of PAS+ 
aggregates in the cerebellum (p<0.001 Epm2b-/- w/o TTT vs 4-PBA and p<0.001 w/o TTT vs 
metformin), pontine (p=0.011 Epm2b-/- w/o TTT vs 4-PBA and p<0.04 w/o TTT vs metformin) 
and hippocampus (p<0.001 Epm2b-/- w/o TTT vs 4-PBA and p<0.001 w/o TTT vs metformin) 
(Fig. 2A and 2B). 
It is known that polyglucosan inclusions that accumulate in LD are also enriched in 
polyubiquitinated proteins ([1], [2]). We confirmed this fact by immunohistofluorescence. As 
it is shown in Fig. 3, untreated Epm2b-/- mice presented high levels of polyubiquitinated 
protein aggregates in cerebellum, pontine and hippocampus, whereas Epm2b+/- control mice 
did not present any of these aggregates. Then, we checked whether the treatment with the 
different drugs reduced the levels of polyubiquitinated protein aggregates present in Epm2b-/- 
mice. Consistent with the results described above, trehalose did not modify or slightly 
increased (pontine: p=0.02; hippocampus: p=0.02) the levels of polyubiquitinated protein 
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aggregates present in the different studied brain areas of the treated animals (Fig. 3). 
However, treatment with 4-PBA or metformin clearly decreased the levels of 
polyubiquitinated protein aggregates in all the assayed areas of the brain (cerebellum: 
p=0.002 [4-PBA], p<0.001 [metformin]; pontine: p=0.004 [4-PBA], p<0.001 [metformin]; 
hippocampus: p<0.001 [4-PBA], p<0.001 [metformin]; cortex: p=0.003 [4-PBA], p<0.001 
[metformin]) (Fig. 3A and 3B). 
 
Neurodegeneration and hippocampal gliosis is reduced by 4-PBA or metformin 
treatments. 
Lafora disease is characterized by neuronal loss and the appearance of the concomitant gliosis 
([2], [33], [34]). We confirmed these facts in the untreated Epm2b-/- mice where we observed 
that selected areas of the hippocampus [dentate gyrus (DG) and cornus ammonis 1 (CA1) 
regions] had reduced NeuN (Neuronal Nuclei) staining, a neuron-specific marker (DG 
p=0.016 and CA1 p=0.006 in untreated control vs Epm2b-/-) (Fig. 4A and 4B). Untreated 
Epm2b-/- mice presented a less compacted staining (see black arrow heads) suggesting the 
loss of neurons in these areas (Fig. 4A). Trehalose treatment did not prevent neuronal loss in 
DG or CA1 areas of the hippocampus (Fig. 4A and 4B). However, when compared with 
untreated Epm2b-/- mice, treatment with 4-PBA or metformin presented a significant higher 
NeuN staining in both analyzed hippocampus regions (DG: p=0.005 [4-PBA], p=0.016 
[metformin]; CA1: p=0.005 [4-PBA], p=0.008 [metformin]), suggesting that these treatments 
prevented neuronal loss.  
 Similar areas of the hippocampus were also stained with an antibody that recognized 
GFAP (glial fibrillary acidic protein), an astrocyte marker (Fig. 5). This staining was higher in 
preparations from untreated Epm2b-/- in comparison to control mice (DG: p=0.006, and CA1: 
p=0.03 in control vs Epm2b-/-) (Fig. 5), confirming the presence of reactive gliosis. 
Treatment of Epm2b-/- with 4-PBA significantly decreased around 20% (p=0.02) and 40% 
(p<0.001) the gliosis in DG and CA1, respectively (Fig. 5). Similarly, metformin treatment 
reduced gliosis around 40% (p<0.001) and 60% (p<0.001) in DG and CA1, respectively (Fig. 
5). Surprisingly, treatment with trehalose also significantly diminished around 40% the 
astrogliosis in both regions (p<0.001 in both cases) (Fig. 5). 
 
Trehalose, 4-PBA or metformin ameliorate some Epm2b-/- neuropsychological 
dysfunctions. 
In addition to the above described molecular and histological analyses, each group of mice 
was subjected to a battery of neuropsychological tests after one month of treatment and also at 
the end of the period of two months of treatment. One of the tests was the tail suspension test 
(TST). Originally designed to screen antidepressant drugs [28], it is based on the fact that 
animals subjected to the short-term, inescapable stress of being suspended by their tail, 
develop an immobile posture with both extended feet. Clasping of the feet is recorded as a 
sign of neurodegeneration. As observed in Fig. 6, untreated Epm2b-/- mice presented a 
significant worse performance than untreated control mice (p=0.002 and p=0.007, after one 
and two months of treatment, respectively). Treatment with 4-PBA or metformin showed a 
tendency to improve the performance after one month of treatment but the differences became 
statistically significant after two months of treatment (p=0.045 [4-PBA] and p=0.017 
[metformin]) (Fig. 6). Trehalose treatment did not improve the performance of Epm2b-/- mice 
in any case. 
 The vertical pole test was originally designed to quantify mouse movement disorders 
in animal models of Parkinson disease [29]. As observed in Fig. 7, untreated Epm2b-/- mice 
presented a significant worse performance than untreated control mice in the time to turn and 
locomotion activity parameters of the test (p=0.018 and p=0.028 after one month of treatment 
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and p<0.001 for both parameters after two months of treatment). Treatment with trehalose 
decreased both parameters of this test (time to turn and locomotion activity) after one month 
of treatment (p<0.001 and p=0.002 respectively) and the amelioration was even higher after 
two months of treatment (p<0.001 for both parameters) (Fig. 7). 4-PBA also improved both 
parameters after one month of treatment (p<0.001 and p=0.03 respectively) and we observed 
a great amelioration of both the time to turn and locomotion activity parameters after the 
second month of treatment (p<0.001 for both) (Fig. 7). After one month, metformin treated 
animals showed a significant improvement in the time to turn parameter (p=0.049) and a clear 
tendency to improve the locomotion activity, although it was not statistically significant. 
However, after two month of treatment the improvement became clearly observed for both 
parameters (p=0.0038 and p=0.0053, for time to turn and locomotion activity, respectively) 
(Fig. 7). 
 Animals were also subjected to additional behavioral tests (open field, used to assay 
general locomotion activity levels and anxiety, Fig. 8; beam balance, used to assay fine motor 
coordination and balance, Fig. 9), but we did not find any significant difference in the 
parameters of these tests between treated or untreated animals, possibly because the 
neurological deterioration present in the Epm2b-/- mice at five months of age could have 
affected some neuropsychological abilities but not others. 
 
DISCUSSION 
More than a century after its description, the progressive myoclonus epilepsy of Lafora type is 
still a fatal disease leading to the death of patients usually within the decade after the 
apparition of the first symptoms. Unfortunately, up to now, available treatments are only 
palliatives and no curative drugs are available yet. Recent reports indicate that the elimination 
of the capacity of the cells to synthesize glycogen, either by depleting glycogen synthase or 
the protein targeting to glycogen (PTG) in animal models of LD ([35], [36], [37], [38]), not 
only results in the elimination of the accumulation of polyglucosans, but also in the 
amelioration of the neuropathological symptoms. These results have led those authors to 
suggest the use of glycogen synthase inhibitors as a putative strategy to treat LD. While the 
field awaits for the beneficial effects that these drugs could have in the future, in this work we 
have used an alternative strategy to find a beneficial treatment for LD based on the restoration 
of proteostasis, which is defective in this disease ([9], [10], [11]). We describe the use 
trehalose and 4-phenylbutyric acid (4-PBA), two chemical chaperones with recognized 
abilities to ameliorate misfolding of proteins ([17], [18], [19], [20], [21]). In addition, we have 
checked the effect of metformin, an activator of AMP-activated protein kinase (AMPK), as 
activation of this kinase plays a neuroprotective role in different neurodegenerative diseases 
([24], [25], [26], [27]).  
 We first observed that the designed treatments affected the corresponding molecular 
targets in the brain of a mouse model of LD (Epm2b-/-, lacking malin): trehalose and 4-PBA 
increased the levels of the chaperone BIP/Grp78, involved in the amelioration of proteostasis 
dysfuction, and metformin induced the activation of the AMPK complex. Then, we analyzed 
the possible beneficial effect of these drugs on LD symptoms. We found that the 
administration of the chemical chaperone 4-PBA reduced the levels of polyglucosan (PAS+) 
and polyubiquitinated protein aggregates in different areas of the brain of Epm2b-/- treated 
mice. This beneficial effect could be due to its action as a chemical chaperone or to its ability 
to improve the expression of the endogenous chaperone BiP/GRP78. The improved chaperone 
content of the cell could diminish the formation of intracellular aggregates. The use of 
trehalose, another small molecule that acts as chemical chaperone also improved the 
expression of BiP/GRP78 but did not have a beneficial effect in reducing intracellular 
aggregates, perhaps because its role as chemical chaperone could not be as potent as 4-PBA. 
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Trehalose and 4-PBA were effective in reducing gliosis in the different parts of the 
hippocampus, but only 4-PBA had in addition a beneficial effect in preventing neuronal loss. 
The different histological effect of these two drugs had a reflection in the performance of the 
treated animals when subjected to different neuropsychological tests: whereas 4-PBA treated 
animals improved the tail suspension and the pole tests, trehalose had only a beneficial effect 
on the pole test. 
 We also describe the beneficial effect of metformin, an activator of AMPK, in the 
treatment of LD. We observed a clear reduction in the number of polyglucosan (PAS+) and 
polyubiquitinated protein aggregates, a reduction of neuronal loss and gliosis in different 
hippocampal regions and an amelioration of the neuropsychological alterations of Epm2b-/- 
treated mice. One possible explanation for the positive effect of metformin on LD could be 
that it maintained a sustained activation of AMPK, and this resulted in neuroprotection. As 
AMPK is involved in the activation of the autophagy pathway, we checked whether treatment 
with metformin could have an effect on autophagy, but as shown in Supplementary Fig. S1, 
we observed no changes in the levels of two recognized autophagy markers, namely LC3B-II 
and p62, upon treatment (trehalose and 4-PBA treatment did not affect these parameters 
either). So, an enhancement of autophagy is not responsible for the beneficial effects of these 
compounds. On the other hand, activation of AMPK may inhibit glycogen synthase [39]. 
However, upon metformin treatment, we did not observe changes in the state of different 
enzymes related to glycogen homeostasis (protein levels and phosphorylated forms of 
glycogen synthase and glycogen synthase kinase 3 were similar in all the cases; 
Supplementary Fig. S2), (trehalose and 4-PBA treatment did not affect these parameters 
either). These results are in agreement with previous reports which indicate that the specific 
activity of glycogen synthase does not change in the brain of LD mouse models in comparison 
to controls, especially at young ages as the ones used in our studies (5 month old animals at 
the end of the treatments) ([40], [41], [42]). Thus, we conclude that the beneficial effect of 
metformin in LD could be due to alternative mechanisms. 
 In conclusion, we describe for the first time the beneficial effect of the administration 
of small molecule compounds on the neuropathological symptoms of LD. It is encouraging to 
see that the beneficial effect of these drugs is already present after one month of treatment and 
much better results are obtained if the treatment is prolonged for two months. As these 
compounds have good safety records and are already approved for clinical use on different 
neurological pathologies, we think their use in clinical practice based on drug repositioning 
could be straightforward. 
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Figure 1: Drugs used in this study affect their corresponding targets in mice brain. Western 
blot analyses of whole brain extracts using the indicated antibodies and densitometric 
quantification of the corresponding blots were carried out as described in Material and 
Methods. A representative blot is presented. (A) anti-BiP/GRP78 (BiP) and anti-actin (loading 
control) from Epm2b+/- (control) and Epm2b-/- (KO) mice untreated (w/o TTT) or treated 
with trehalose (2%) or 4-PBA (20 mM) for two months. *p<0.05, **p<0.01 (n: 3 [control] or 
n:4 [KO]) comparing the indicated groups with the basal condition according to Kruskal-
Wallis non-parametric test followed by Conover-Inman post-hoc test. (B) anti-pThr172-
AMPKalpha (pAMPK) and anti-AMPK1/2 (loading control) from Epm2b+/- control and 
Epm2b-/- (KO) mice untreated (w/o TTT) or treated with 12 mM metformin for two months. 
Bars indicate mean values of the relative intensity of each protein of at least three independent 
samples ± SEM. Asterisks denote significant differences *p<0.05, (n: 3 [control] or n:4 [KO]) 
comparing the indicated groups with the basal condition according to the Wilcoxon-Mann-
Whitney test. 
 
Figure 2: Histological analyses of PAS+ inclusions in brain of Epm2b+/- (control) or Epm2b-
/- (KO) mice untreated (w/o TTT) or treated with trehalose, 4-PBA or metformin (two months 
each). (A) Representative frontal sections of the cerebellum, pontine and hippocampus from 
Epm2b+/- control or Epm2b-/- (KO) mice untreated (w/o TTT) or treated as indicated in the 
text, were stained with periodic acid-Schiff (PAS) and counterstained with haematoxylin. 
Black arrow heads point to Lafora bodies. Scale bars: 25 µm. (B) PAS+ inclusions were 
counted by eye in three independent samples of cerebellum, pontine, hippocampus, olfactive 
bulb, cerebral cortex and midbrain of seven mice of each group, and mean quantification of 
the number of polyglucosan inclusions in an area of 0.09 mm2 was represented. Bars indicate 
mean of values corresponding to seven mice ± SEM. Asterisks denote significant differences 
*p< 0.05, **p< 0.01, ***p<0.001 comparing the indicated groups with the basal condition 
(Epm2b-/- w/o TTT) according to Kruskal-Wallis non-parametric test followed by Conover-
Inman post-hoc test. 
 
Figure 3: Immunohistofluorescence analyses of polyubiquitinated protein aggregates in brain 
of Epm2b+/- (control) or Epm2b-/- (KO) mice untreated (w/o TTT) or treated with trehalose, 
4-PBA or metformin (two months). (A) Representative frontal sections of the cerebellum, 
pontine, hippocampus and cortex from Epm2b+/- control or Epm2b-/- KO mice untreated 
(w/o TTT) or treated as indicated, were incubated with anti-polyubiquitin antibody and 
AlexaFluor488 conjugated anti-rabbit antibody. Scale bars: 100 µm. (B) Polyubiquitin-
associated fluorescence was quantified with ImageJ software in two independent pictures of 
cerebellum, pontine, hippocampus and cerebral cortex from five mice per group, and mean 
fluorescence in an area of 0.4 mm2 was represented. Bars indicate mean of fluorescence 
values corresponding to five mice ± SEM. Asterisks denote significant differences *p< 0.05, 
**p< 0.01, ***p<0.001 comparing the indicated groups with the basal condition (Epm2b-/- 
w/o TTT) according to Kruskal-Wallis non-parametric test followed by Conover-Inman post-
hoc test. 
 
Figure 4: Immunohistochemistry analyses of neurodegeneration in hippocampus of 
Epm2b+/- (control) and Epm2b-/- (KO) mice untreated (w/o TTT) or treated with trehalose, 
4-PBA or metformin (two months). (A) Representative frontal sections of the dentate gyrus  
(DG) and the cornus ammonis 1 (CA1) of the hippocampus from Epm2b+/- control or 
Epm2b-/- KO mice untreated (w/o TTT) or treated as indicated, were incubated with anti-
NeuN (Neuronal nuclei) antibody. Black arrow heads point to empty space between neurons 
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in DG. Scale bars 25 µm. NeuN-positive and negative cells were counted in DG (B) and CA1 
(C) sections from three independent mice and percentage of NeuN-postive cells in an area of 
0.09 mm2 was represented. Bars indicate mean values corresponding to three independent 
mice ± SEM. Asterisks denote significant differences *p< 0.05 **p<0.01 comparing the 
indicated groups with the basal condition (Epm2b-/- w/o TTT) according to Kruskal-Wallis 
non-parametric test followed by Conover-Inman post-hoc test. 
 
Figure 5: Immunohistofluorescence analyses of gliosis in hippocampus of Epm2b+/- 
(control) or Epm2b-/- (KO) mice untreated (w/o TTT) or treated with trehalose, 4-PBA or 
metformin (two months). (A) Representative frontal sections of the dentate gyrus (DG) and 
the cornus ammonis 1 (CA1) of the hippocampus from Epm2b+/- control or Epm2b-/- KO 
mice untreated (w/o TTT) or treated as indicated, were incubated with anti-GFAP (glial 
fibrillary acidic protein) antibody and AlexaFluor488 conjugated anti-rabbit antibody and 
counterstained with DAPI to show the area where the analysis was performed (insets). Scale 
bars 100 µm. GFAP-associated fluorescence was quantified with ImageJ software in two 
pictures from DG (B) and CA1 (C) sections from five mice per group, and mean fluorescence 
in an area of 0.26 mm2 was represented. Bars indicate mean of fluorescence values 
corresponding to five mice ± SEM. Asterisks denote significant differences *p< 0.05 
***p<0.001 comparing the indicated groups with the basal condition (Epm2b-/- w/o TTT) 
according to Kruskal-Wallis non-parametric test followed by Conover-Inman post-hoc test. 
 
Figure 6: Tail suspension test of Epm2b+/- (control) and Epm2b-/- (KO) mice untreated (w/o 
TTT) or treated with trehalose, 4-PBA or metformin, during one (A) or two months (B). 
Percentage of Epm2b+/- (control) or Epm2b-/- (KO) mice showing normal posture (0) or 
altered (1) stereotypical clasping of the hind-limb upon tail suspension (n: 8-11 in each 
group). Significant differences between the groups were indicated (*p< 0.05, **p< 0.01) 
according to the Fisher exact test followed by Wilcoxon-Mann-Whitney test. 
 
Figure 7: Vertical pole test for evaluation of motor coordination of Epm2b+/- (control) and 
Epm2b-/- (KO) mice untreated (w/o TTT) or treated with trehalose, 4-PBA or metformin, 
during one (A-B) or two months (C-D). After one month of treatment, the time taken by the 
mice to turn completely downward (time to turn) (A) and the total time taken to reach the 
floor (locomotion activity) (B) were recorded. After two months of treatment, the time to turn 
(C) and the locomotion activity (D) were also recorded. Bars indicate mean of values 
corresponding to eight to twelve mice ± SEM. Asterisks denote significant differences 
between the groups (*p< 0.05, **p< 0.01, ***p< 0.001) according to Kruskal-Wallis non-
parametric test followed by Conover-Inman post-hoc test). 
 
Figure 8: Open-field analyses of Epm2b+/- (control) and Epm2b-/- (KO) mice untreated (w/o 
TTT) or treated with the described drugs during one month (A, C, E, G) or two months (B, D, 
F, H). No significant differences between groups (n: 8-12 mice in each group) were observed 
in all recorded parameters: total distance roamed (A-B), total immobility time (C-D), number 
of entries in the more central zone (zone 3) (E-F), or the distance roamed in zone 3 (G-H), 
according to Kruskal-Wallis non-parametric test followed by Conover-Inman post-hoc test. 
 
Figure 9: Beam-balance analyses of Epm2b+/- (control) and Epm2b-/- (KO) mice untreated 
(w/o TTT) or treated with the described drugs during one month (A) or two months (B). No 
significant differences between groups (n: 8-12 mice in each group) were observed in the time 
to cross the beam in any of the beam sizes analyzed (5, 12 and 26 mm), according to Kruskal-
Wallis non-parametric test followed by Conover-Inman post-hoc test. 
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